Cases of filgrastim overdose have not marked. After 1-2 days after discontinuation of the drug the number of circulating neutrophils is usually reduced by 50% and masteron returns to normal 1-7 days.
Interaction with other drugs
Efficacy and safety of filgrastim administration in one day with cytotoxic chemotherapy have not been established. Due to the high sensitivity of actively proliferating myeloid cells to cytotoxic anticancer drugs assign filgrastim 24 hours before or after administration of these drugs is not recommended.
Fluorouracil enhances the severity of neutropenia, while the appointment with filgrastim. Possible interactions with other hematopoietic growth factors and cytokines is unknown.
Given that lithium promotes the release of neutrophils, may increase in the combined action of filgrastim appointment, but such studies have not been conducted.
Filgrastim pharmaceutically incompatible with 0.9% sodium masteron chloride solution. In the application of filgrastim for the mobilization of hematopoietic stem cells after chemotherapy should be noted that when administered for a long time such cytostatics as melphalan, carmustine and carboplatin, the effectiveness of mobilization can be reduced.
Treatment with Tevagrastim should be conducted only under the supervision of an oncologist or hematologist with experience in the use of masteron with the necessary diagnostic capabilities. mobilization and apheresis procedures should be performed in cell oncology or hematology center with experience in this field and the possibility of adequate monitoring of hematopoietic progenitor cells.
Syringe, in which the solution can be equipped with additional safety needle device or be without. Additional safety device designed to prevent injuries and shots already used syringes (needles) and does not require any special precautions. Solution necessary for administration to press slowly and evenly on the syringe plunger. The pressure on the piston is maintained until the introduction of the recommended dose, and remove the syringe from the injection site. Used syringes disposed of in accordance with the instructions of the doctor or medical institution. Syringes without safety device before discarding placed in a container made of durable material.
Precautions for patients with acute myeloid leukemia
growth of malignant cell human masteron can stimulate the growth of myeloid cells in vitro. Similar effects can be observed in vitro and in relation to certain non-myeloid cells.
In myelodysplastic syndrome and chronic myeloid leukemia efficacy and safety of filgrastim has not been established. Patients with the above diseases, as well as precancerous lesions of myeloid blood, the use of filgrastim is not indicated. Particular attention should be paid to the differential diagnosis between the blast crisis of chronic myeloid leukemia and acute myeloid leukemia.
Caution should be exercised when using the drug in patients with Tevagrastim secondary myelocytic leukemia masteron as the limited data on safety and efficacy.